Marksans Pharma Ltd's earnings have grown by 7.7%, whereas share price has appreciated 5.6% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.
Marksans Pharma Ltd share price has appreciated 41.1% annually (CAGR) over the past ten years.
Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Marksans Pharma Ltd is an average long term investment. However, you need to ensure you buy at a right price to earn good returns.
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.
Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.
The company, engaged in
The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.
Marksans Pharma acquired Relonchem, a leading UK-based generic pharmaceutical company. This acquisition gave company an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe.
Marksans Pharma exports its products to markets in Europe, Latin America, Africa and Oceania.
In 2010 Company entered into a Business Transfer Agreement with Kores (India) LimitedBusiness area
Research and Development- The companyâ€™s R&D centre is situated in Goa and is engaged in new drug discovery chemistry, pharmacokinetics, pharmacology/ molecular biology, toxicology, and related skills and support areas.
Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in Asia. The companyâ€™s manufacturing plants are located at Goa and UK.
APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.
CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.
2009 - Marksans Pharma establlished itself as a global player2008 - Acquired Bells, Sons & Co. (Druggists) Ltd. Acquired Relonchem Limited2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd. Changed its name to "Marksans Pharma Ltd"2001 - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.